Oxford Expression Technologies Limited

Funded awards at Oxford Expression Technologies Limited.

Funded awards

Total Funding

£5.1M

Average published award

£634K

Active funded awards

Data as of 16 July 2026

The biggest topic here is Infection & Immunity — 7 grants (88%). The busiest year was 2016, with 2 grants.

Funder	Funded awards
Infection & Immunity	7
Diabetes, Hormones & Metabolism	1

Funded Awards by Year

View data table


Development of an economically viable CCHF virus vaccine	Oxford Expression Technologies Limited	InnovateUK	£2.2M	2018	Completed
CCHFv vaccine for LMICs - transition from preclinical to clinical studies	Oxford Expression Technologies Limited	InnovateUK	£1.4M	2023	Completed
Covid-19: a rapidly scalable SARS-Cov-2 vaccine platform based on recombinant spoke protein manufactured in insect cells using flashBAC to maximise yield and quality	Oxford Expression Technologies Limited	InnovateUK	£545K	2020	Completed
Development of a subunit vaccine against CCHF virus for use in low-middle income countries; completion of pre-clinical studies	Oxford Expression Technologies Limited	InnovateUK	£377K	2022	Completed
Newton Fund - Pretransplant gene therapy of pancreatic islet tissue; towards a therapy for Diabetes type I in Mexico	Oxford Expression Technologies Limited	InnovateUK	£276K	2016	Completed
Development of an economically viable CCHF virus vaccine for local production	Oxford Expression Technologies Limited	InnovateUK	£217K	2016	Completed
A novel production system for virus-like particle vaccines	Oxford Expression Technologies Limited	InnovateUK	£57K	2014	Completed
COVID 19: a rapidly scaleable SARS-CoV-2 vaccine in insect cells	Oxford Expression Technologies Limited	InnovateUK	£10K	2021	Completed